SAN DIEGO, Aug. 11, 2015 /PRNewswire/ -- Forge Therapeutics, Inc., a biotechnology start-up developing novel small molecule inhibitors that target metalloproteins announced today its participation at the 250th American Chemical Society National Meeting taking place at the Boston Convention Center from August 16-20, 2015.
Dr. Seth Cohen, Ph.D., co-founder of Forge Therapeutics and Professor in the Department of Chemistry and Biochemistry at the University of California, San Diego is presiding over and presenting at a session entitled 'Metalloprotein Inhibitors: Drugs, Drug Candidates, and New Targets at the Interface of Medicinal and Inorganic Chemistry' on Monday August 17th from 1:30pm to 5:20pm in Room 160C Boston Convention & Exhibition Center.
Dr. Cohen's presentation 'Structural Studies on Metal-Binding Pharmacophores for Metalloprotein Inhibitors' from 2:50pm to 3:25pm will focus on a fragment-based drug discovery approach to identify the best ligands for a given metalloenzyme target.
"At Forge Therapeutics we are pleased that Dr. Cohen's research is being recognized as an innovative approach to fill the void in metalloprotein inhibitor chemistry," said Zachary A. Zimmerman, Ph.D., CEO of Forge Therapeutics. "The scientific advancements made by Dr. Cohen serve as the foundational technology for Forge Therapeutics platform."
To learn more about the session on metalloproteins please visit https://ep70.eventpilotadmin.com/web/page.php?page=Session&project=ACS15fall&id=200104
About Forge Therapeutics, Inc.
Forge Therapeutics, Inc. ("Forge") is a biotechnology start-up that leverages its novel chemistry platform to develop small molecule inhibitors to target metalloproteins. Metalloproteins are proteins that require metal ions for their biological function and make up over 1/3 of the proteins in the human body. Forge uses a proprietary approach comprised of molecular modeling for rational drug design along with fundamental knowledge and expertise in bioinorganic chemistry to target metalloproteins. Forge is uniquely positioned to discover compounds that inhibit metalloproteins through an innovative process developed at the University of California at San Diego. Forge possesses rights to key intellectual property for metalloprotein inhibitors. The name Forge Therapeutics comes from two definitions for forge: to manipulate (inhibit) a metal object (metalloprotein) and to move forward steadily with a purpose (the Forge team). Forge Therapeutics, Inc., maintains its headquarters in San Diego, California. To learn more please visit www.ForgeTherapeutics.com
SOURCE Forge Therapeutics, Inc.